What exactly did the FDA approve?
The FDA approved Zepbound on December 20, 2024, to treat moderate to severe obstructive sleep apnea in adults with obesity, alongside a reduced-calorie diet and more physical activity. It was the first medicine approved for obstructive sleep apnea. The agency said the improvement in breathing during sleep was likely related to the weight loss tirzepatide produces.
The Zepbound label defines moderate to severe as an apnea-hypopnea index (AHI) of 15 or more events per hour and obesity as a BMI of 30 or more. The maintenance doses for sleep apnea are 10 mg or 15 mg weekly, reached by the same slow climb used for weight loss. Those numbers are background, and the dose you take is set by your provider.
What did the SURMOUNT-OSA trials find?
Two 52-week trials enrolled 469 adults without type 2 diabetes. One included people unable or unwilling to use positive airway pressure (PAP), and the other included people already on PAP, who paused it for a week before the final sleep study. Average starting AHI was about 50 events an hour, firmly in the severe range.
| Week 52 result | No PAP: tirzepatide | No PAP: placebo | On PAP: tirzepatide | On PAP: placebo |
|---|---|---|---|---|
| Change in AHI (events per hour) | -25.3 | -5.3 | -29.3 | -5.5 |
| Percent change in AHI | -50.7% | -3% | -58.7% | -2.5% |
| Remission or mild, symptom-free OSA | 42.2% | 15.9% | 50.2% | 14.3% |
| Change in body weight | -17.7% | -1.6% | -19.6% | -2.3% |
The published trial report also found improvements in oxygen drops overnight, sleep-related symptoms, systolic blood pressure and the inflammation marker hs-CRP. The most common side effects were digestive and mostly mild to moderate.
Why does weight loss help sleep apnea?
Because excess weight narrows the airway. The NHLBI lists obesity among the main risk factors for obstructive sleep apnea and notes that untreated sleep apnea raises the risk of stroke, heart attack and other serious problems. Losing fat around the neck and upper body takes pressure off the airway during sleep, which is consistent with the FDA’s view that tirzepatide’s effect runs mostly through weight loss.
That also explains the limits. Sleep apnea driven by jaw shape, large tonsils or other anatomy may improve less with weight loss alone.
Who is this approval not for?
The approval is specific. It does not cover:
- Men without obesity, since all trial participants had a BMI of 30 or more
- Central sleep apnea, which has a different cause
- Sleep apnea that has never been confirmed with a sleep study
- Replacing PAP on your own; the trials did not test when stopping PAP is appropriate
Sleep studies are not part of the Ultimate Male service menu, so if you snore, gasp at night or wake unrefreshed and have never been tested, the first step is a sleep evaluation through your primary care clinician or a sleep specialist.
Related question: does sleep apnea affect testosterone?
It can. Poor, broken sleep and low oxygen overnight are linked with lower testosterone, and the two problems often travel together in men with obesity. Our page on sleep apnea and low testosterone explains the connection, and starting TRT with sleep apnea covers why untreated apnea matters before testosterone therapy. For the regulatory story behind the approval, see our Zepbound sleep apnea approval article.
How Ultimate Male fits tirzepatide into sleep apnea care
At Ultimate Male, tirzepatide is one of two GLP-1 based medicines in the medical weight loss program. If you already have a sleep apnea diagnosis, bring your sleep study report to the consultation. A PA-C or MD reviews it with your labs, blood pressure, body composition and medicines to decide whether tirzepatide makes sense, and the plan keeps your sleep clinician informed.
You can read how the tirzepatide weight loss program runs, from dose climb to check-ins. To ask whether you are a candidate, start with the free 10-minute call at 626-319-5261.
